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A B S T R A C T
Molecular typing has been used extensively to study the epidemiology of infection, but there are few
studies on the role of typing in the clinical management of infected patients. Examples of this include
distinguishing relapse of infection from new infection, determining the significance of colonisation with
potential pathogens, assessing the capacity of isolates to spread and cause serious illness, and linking
changes in antimicrobial resistance with treatment. Further studies in selected patient groups and
greater collaboration between molecular microbiologists, clinical microbiologists and infectious disease
physicians are required to determine the impact of molecular typing in these and other scenarios.
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Typing sub-divides species and determines whe-
ther or not members of the same species are
indistinguishable. Typing methods should give
reproducible results in the laboratory and in a
clinical context [1]. However, much research on
typing methodology concentrates on studying the
epidemiology of infection [1–5]. The role of
molecular typing in clinical management, inclu-
ding guiding therapy, is different from that of
high-throughput epidemiological typing to track
the spread of microorganisms, as reviewed
recently in this journal [6]. Under what circum-
stances may typing determine the extent of
infection and influence treatment in the individual
patient?
Distinguishing relapse from reinfection, and
determining if an isolate is of pathogenic signifi-
cance, is important clinically. In a study of 244
hospitalised patients with Staphylococcus aureus
bacteraemia, pulsed-field gel electrophoresis
(PFGE) was used to determine whether a second
episode of bacteraemia was caused by an isolate
indistinguishable from the first, i.e., relapse [7].
Patients treated according to recommended pro-
tocols were less likely to relapse. Therefore,
should sequential isolates from a patient with
recurrent bacteraemia be typed routinely to con-
firm relapse associated with inadequate treat-
ment? In some situations it would be helpful to
predict whether colonisation with S. aureus will
lead to invasive infection. In a separate study [8],
nasal and peritoneal dialysis catheter exit-site
swabs were taken from 41 patients, and isolates of
S. aureus were compared by phage-typing and
PFGE. Exit-site infection with the same strain was
higher in nasal carriers, and therefore eradication
of nasal carriage to prevent infection in dialysis
patients was supported by molecular typing [9].
PFGE has also been used to compare isolates of
coagulase-negative staphylococci (CNS) recov-
ered from eyelid cultures and intra-ocular com-
partments to identify the cause of infection in
patients with endophothalmitis [10]. Over two-
thirds of paired (eyelid and intra-ocular) CNS
isolates were indistinguishable. It may therefore
be appropriate to characterise isolates from super-
ficial sites in serious eye infections when other
specimens are unobtainable, as these isolates are
likely to be the same as those causing the
intra-ocular infection.
Patients in the intensive care unit and patients
with cystic fibrosis are often colonised with
potential pathogens, but assessing their clinical
significance is difficult. In a study comparing two
drug regimens to reduce gastric ulcers caused by
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stress in very ill patients, restriction endonuclease
analysis of plasmid DNA and chromosomal
DNA was used to type bacterial isolates [11].
The incidence of post-operative pneumonia was
40% among 140 patients colonised in the gastric
mucosa vs. 12% in non-colonised patients. Isolates
recovered from gastric aspirates reflect the aetiol-
ogy of subsequent pneumonia; therefore typing of
colonising isolates, in combination with antimi-
crobial susceptibility testing, may help in the
development of empirical antibiotic guidelines,
thereby resulting in better patient management.
Colonisation and infection with organisms of
the Burkholderia cepacia complex is a major concern
for patients with cystic fibrosis. In a study of
isolates characterised by random amplified poly-
morphic DNA and PFGE, genomovar III strains
were more likely to spread between patients and
were associated with a higher mortality [12]. An
in-vitro study demonstrated that isolates belong-
ing to genomovars II and III were especially
invasive [13]. Consequently, it is essential to
determine the genomovar of B. cepacia isolates,
as this will indicate the possibility of spread and
the likelihood of infection.
Identification of antibiotic resistance genes by
molecular methods, particularly when the mech-
anism can be associated clearly with a specific
complex, has been used to guide therapy. For
example, 120 vancomycin-resistant Enterococcus
faecium isolates from outbreaks were compared
with 45 non-epidemic isolates by amplified frag-
ment length polymorphism analysis [14]. The esp
gene was highly conserved in isolates that caused
hospital outbreaks, and confirmed this gene as a
recognised virulence factor. Would a routine
molecular search for this gene, particularly when
the isolate is recovered from a normally non-sterile
site such as a wound or urine, help to determine
whether the patient should be treated? As a further
example, 12 patients infected with HIV were
monitored at regular intervals to detect colonisa-
tion with Candida spp. when receiving fluconazole
prophylaxis [15]. Molecular typing revealed DNA
changes in isolates with similar MICs recovered
before and after treatment, indicating possible
selective pressures in response to environmental
signals, including exposure to antifungal agents.
Would an assessment of DNA patterns, in combi-
nation with antifungal susceptibility testing, help
predict the likelihood of subsequent or persistent
infection with susceptible or resistant isolates?
Increasingly, treatment of infection is dominated
by protocols, and molecular typing may have a role
in these. Diagnosis of intravascular catheter-rela-
ted infections caused by CNS is dependent in
practice on the isolation of indistinguishable iso-
lates from peripheral and catheter blood cultures,
and from the tip of the removed intravascular
catheter [16]. Phenotypic variation among CNS is
considerable, and most laboratories use speciation
and antimicrobial susceptibility patterns, which
are unreliable, to assess differences. Molecular
confirmation that isolates recovered from periph-
eral and catheter blood cultures were different, and
hence represented probable contamination, would
mean that fewer intravascular devices would be
removed unnecessarily.
In the most recent molecular innovation, DNA
microarrays have been used to study the patho-
genesis of infection [17], but this does not impact
greatly on patient care. Pfaller [18] has argued
that genotyping will not replace phenotypic
methods for detecting antimicrobial resistance in
the near future, but acknowledged the potential of
molecular typing in distinguishing between colo-
nising and infecting isolates, in differentiating
between contaminating and infecting strains, in
confirming the potential for nosocomial transmis-
sion of pathogens, and in evaluating reinfection
vs. relapse in patients with S. aureus bacteraemia,
all of which have been discussed earlier with
examples of potential clinical benefits. However,
most typing facilities are at a distance from the
patient, the results are not available in real time,
and it has not been proven conclusively that
molecular typing improves patient care directly,
or is cost-effective. Further studies on selected
groups of patients are required, and molecular
microbiologists, clinical microbiologists and infec-
tious disease physicians must collaborate much
more to answer these questions. Otherwise,
molecular typing will remain largely a research
tool confined to epidemiological studies and will
never reach the bedside!
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